Literature DB >> 18256604

Battle over eye medicine gives drugmaker a dose of reality.

Erika Check Hayden.   

Abstract

Mesh：

Substances：

Year:  2008        PMID： 18256604     DOI： 10.1038/nm0208-108

Source DB:  PubMed          Journal:  Nat Med        ISSN： 1078-8956            Impact factor:   53.440


× No keyword cloud information.
  3 in total

1.  Provider, patient and public benefits from a NICE appraisal of bevacizumab (Avastin).

Authors:  Catherine Rhodes; John Harris; John Sulston; Catherine Spanswick
Journal:  J Med Ethics       Date:  2011-09-24       Impact factor: 2.903

Review 2.  Off-label use of bevacizumab for the treatment of age-related macular degeneration: what is the evidence?

Authors:  Focke Ziemssen; Salvatore Grisanti; Karl Ulrich Bartz-Schmidt; Martin S Spitzer
Journal:  Drugs Aging       Date:  2009       Impact factor: 3.923

3.  A combinatorial approach for the design of complementarity-determining region-derived peptidomimetics with in vitro anti-tumoral activity.

Authors:  Peter Timmerman; Rodrigo Barderas; Johan Desmet; Danièle Altschuh; Susana Shochat; Martine J Hollestelle; Jo W M Höppener; Alberto Monasterio; J Ignacio Casal; Rob H Meloen
Journal:  J Biol Chem       Date:  2009-10-06       Impact factor: 5.157
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.